Literature DB >> 25617148

Therapeutic effects of resveratrol in a mouse model of HDM-induced allergic asthma.

Jiaxiang Chen1, Hao Zhou2, Jinlei Wang1, Baoping Zhang1, Fen Liu1, Jian Huang1, Jia Li1, Jiari Lin1, Jiali Bai3, Renping Liu4.   

Abstract

Asthma is an inflammatory disease of the lungs characterized by airway remolding. In this study, we examined whether resveratrol exerts protective effects on allergic asthma in a murine model. To investigate the effects of resveratrol on allergic airway inflammation in house dust mite (HDM)-induced mouse asthma and explore its mechanism, a chronic asthma mouse model was established by intranasally administering extracts of HDM (25μg of protein in 10μl of saline) for 5days/week for up to 7 consecutive weeks. Resveratrol (50mg/kg body weight), dexamethasone (1mg/kg body weight) or a vehicle was administered orally 1h before antigen challenges for up to 2weeks. Compared with the HDM-induced mice, the level of TNF-α of the BALF in the resveratrol+HDM-treated mice had obviously decreased. Histological examination of the lung tissue revealed that the resveratrol treatments attenuated the fibrotic response and airway inflammation. In addition, resveratrol inhibited the expression of the Syk protein and degranulation in mast cells. The presented findings collectively suggest that resveratrol has a therapeutic effect on mouse allergic asthma, and its mechanism of action might be related to reducing the production of the Syk protein.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Airway inflammation; Allergic asthma; Resveratrol; Syk

Mesh:

Substances:

Year:  2015        PMID: 25617148     DOI: 10.1016/j.intimp.2015.01.013

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  18 in total

1.  Therapeutic Effects of Resveratrol in a Mouse Model of LPS and Cigarette Smoke-Induced COPD.

Authors:  Jinlong Chen; Xu Yang; Weiya Zhang; Danhua Peng; Yanan Xia; Yi Lu; Xiaodong Han; Guangjie Song; Jing Zhu; Renping Liu
Journal:  Inflammation       Date:  2016-12       Impact factor: 4.092

2.  Therapeutic effects of stemonine on particulate matter 2.5-induced chronic obstructive pulmonary disease in mice.

Authors:  Jinbo Zhang; Shiqing Li; Li Sun; Yanxia Chen; Lei Zhang; Zhenghui Zhang
Journal:  Exp Ther Med       Date:  2017-09-01       Impact factor: 2.447

Review 3.  NF-kappaB Signaling in Chronic Inflammatory Airway Disease.

Authors:  Michael Schuliga
Journal:  Biomolecules       Date:  2015-06-26

4.  Resveratrol in Asthma: A French Paradox?

Authors:  Hye Young Kim
Journal:  Allergy Asthma Immunol Res       Date:  2017-01       Impact factor: 5.764

Review 5.  Resveratrol as a potential therapeutic drug for respiratory system diseases.

Authors:  Xiao-Dan Zhu; Xiao-Ping Lei; Wen-Bin Dong
Journal:  Drug Des Devel Ther       Date:  2017-12-15       Impact factor: 4.162

Review 6.  The Toxicological Mechanisms of Environmental Soot (Black Carbon) and Carbon Black: Focus on Oxidative Stress and Inflammatory Pathways.

Authors:  Rituraj Niranjan; Ashwani Kumar Thakur
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

7.  Effects of resveratrol and genistein on nuclear factor‑κB, tumor necrosis factor‑α and matrix metalloproteinase‑9 in patients with chronic obstructive pulmonary disease.

Authors:  Xiao-Ju Liu; Hai-Rong Bao; Xiao-Li Zeng; Jun-Ming Wei
Journal:  Mol Med Rep       Date:  2016-03-28       Impact factor: 2.952

8.  Chronic asthma and Mesenchymal stem cells: Hyaluronan and airway remodeling.

Authors:  Benjamin D Goldstein; Mark E Lauer; Arnold I Caplan; Tracey L Bonfield
Journal:  J Inflamm (Lond)       Date:  2017-08-30       Impact factor: 4.981

9.  Therapeutic effects of Hedyotis diffusa Willd in a COPD mouse model challenged with LPS and smoke.

Authors:  Renping Liu; Peihong Wang; Caiqing Wu; Juan Chen; Chengxin Li; Yongtao Xie; Qi Wang; Jianming Liu; Huan He; Jing Zhu
Journal:  Exp Ther Med       Date:  2018-02-08       Impact factor: 2.447

10.  Different effects of acetyl-CoA carboxylase inhibitor TOFA on airway inflammation and airway resistance in a mice model of asthma.

Authors:  Fang-Fang Zhu; Yi-Min Wang; Guang-Zhen He; Yi-Fei Chen; Ya-Dong Gao
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.